io.veracyte.comVeracyte global diagnostics company

Tests Diseases areas Cancer Thyroid cancer Prostate cancer Lung cancer Breast cancer Bladder cancer Other Interstitial lung disease Portfolio and test expansion Products Thyroid Cancer Afirma Genomic Sequencing Classifier Prostate Cancer Decipher Prostate Genomic Classifier Breast Cancer Prosigna Breast Cancer Assay Interstitial Lung Disease Envisia Genomic Classifier Bladder Cancer Decipher Bladder Genomic Classifier Instructions for use Quality certificates Safety data sheets Enabling global access Pipeline Portfolio and test expansion Enabling global access Who we are Publications Partner Services Biopharma services IVD services CompanyWho we are Leadership Corporate recognition Culture Contact News & Events News Press releases In the news Who we are Events Careers Culture Job openings Investors Overview Press Releases Events & Presentations Financials SEC filings Quarterly results Annual reports Stock information Analyst coverage ESG information Governance Governance overview Board of directors Committee Composition Leadership ESG information Annual reports Investor Resources Investor FAQs Information request Email alerts Annual reports AT VERACYTE WE BELIEVE Exceptional cancer care begins with exceptional diagnostics. Who we are News update C2i Genomics is now a part of Veracyte Press release Veracyte’s molecular tests empower clinicians with the high-value insights they need in the race to diagnose and treat cancer. THYROID CANCER Afirma® Genomic Sequencing Classifier PROSTATE CANCER Decipher® Prostate Genomic Classifier BREAST CANCER Prosigna® Breast Cancer Assay ILD Envisia® Genomic Classifier Bladder Cancer Decipher® Bladder Genomic Classifier PROVIDING HIGH-VALUE INSIGHTS Clinicians and patients may struggle with uncertainty during cancer diagnosis and treatment decision-making. Our tests can help them move forward with confidence. Portfolio and test expansion Tests that help clinicians guide and assure patients at pivotal moments There are pivotal moments in a patient’s cancer care journey where key decisions can impact the patient’s pathway and outcome. Whether diagnosing suspicious symptoms or determining treatment next steps, deciding on the best path forward can be a challenging and uncertain endeavor without the right data. Veracyte’s tests provide answers that enable clinicians and their patients to make more informed and confident decisions. Our diagnostic and prognostic tests provide clarity for some of the most complex diseases, helping patients avoid unnecessary procedures and speeding time to appropriate diagnosis and treatment. ELEVATING THE STANDARD OF CARE FOR TOMORROW Understanding cancer at the molecular level enables more personalized approaches to diagnosis and treatment. Veracyte’s tests deliver actionable insights rooted in both the known and the novel. OUR proven framework Veracyte’s approach to diagnostics We collaborate closely with clinicians and scientists to identify unmet needs that stand in the way of better care. And then, we find the answers. Our rigorous process enables more confident decision-making for clinicians, giving patients access to a higher standard of care. We seek to make leading diagnostics accessible to patients all over the world. 400K The number of patients our tests have benefited. 1 7M The number of people globally each year who are diagnosed with a cancer that our tests address. 2-4 1 Identify clinical unmet needs We work with clinicians and scientists to develop our tests. Through a rigorous multi-disciplinary innovation process we identify unmet needs and create solutions that make clinicians’ and patients’ lives easier. 2 Develop high-performance tests We take a rigorous approach to ensuring product performance and utility, building evidence across a broad range of studies. Clinicians and patients need high-quality, reliable results they can trust. 3 Ramp patient testing globally We make our leading diagnostics widely available through a flexible CLIA- and in vitro diagnostic (IVD)-based model. We supplement this with our proven ability to build clinical evidence that drives reimbursement, encourages clinician adoption, and prompts guideline inclusion for our tests. ESG Report Veracyte’s Environmental, Social and Governance (ESG) Report sets the foundation for our ESG performance and articulates our ambitions to build a more sustainable, equitable future. ESG Report Making our tests available worldwide Through our centralized CLIA lab-based approach in the US and our growing menu of distributed IVDs to serve global markets, we aim to transform cancer care for patients all over the world. Enabling global access Join our team Veracyte offers fulfilling career opportunities for curious, driven, and patient-oriented people who are inspired to find answers to some of the most challenging questions in medicine. Join us. Working at Veracyte REFERENCES Company data on file. Cancer. World Health Organization. Published February 3, 2022. Accessed July 19, 2023. https://www.who.int/news-room/fact-sheets/detail/cancer Thyroid Cancer – Statistics. Cancer.Net. Accessed July 19, 2023. https://www.cancer.net/cancer-types/thyroid-cancer/statistics Bladder Cancer. International Agency for Research on Cancer. Accessed July 19, 2023. https://www.iarc.who.int/cancer-type/bladder-cancer/ © 2024 Veracyte, Inc. All rights reserved. Offices South San Francisco, CA 6000 Shoreline Court, Suite 300 South San Francisco, CA 94080 United States Marseille, France 163 Avenue de Luminy Marseille 13009 FRANCE San Diego, CA 6925 Lusk Boulevard, Suite 200 San Diego, CA 92121 United States Austin, TX 12357-A Riata Trace Parkway Building 5, Suite 100 Austin, TX 78727 United States Haifa, Israel Nahum Het 7 Haifa, Israel 3508506 ISRAEL Helpful links Privacy information center Terms of Use Terms of Sale No Surprises Act Business ethics and compliance Cookies settings Connect Contact LinkedIn X (Twitter)...